| Variable . | Glioblastoma . | Astrocytoma (IDH1/2-mut) . | Oligodendro-glioma . | Pediatric-type Glioma . | Other IDH1/2-wild-type gliomas . |
|---|---|---|---|---|---|
| Patients, n | 2195 | 1198 | 531 | 205 | 271 |
| Cohort, n (%) | |||||
| TCGA NCI | 325 (14.8) | 266 (22.2) | 164 (30.9) | 5 (2.4) | 12 (4.4) |
| DFCI/BWH | 791 (36.0) | 358 (29.9) | 176 (33.1) | 96 (46.8) | 144 (53.1) |
| Genie (v10) | 1079 (49.2) | 574 (47.9) | 191 (36.0) | 104 (50.7) | 115 (42.4) |
| Sex (female), n (%) | 886 (40.4) | 483 (40.3) | 250 (47.2) | 95 (46.3) | 115 (42.4) |
| Median age, years (range) | 61 (6-94) | 36 (7-90) | 43 (13-81) | 27 (1-78) | 51 (0-90) |
| Age (years), n (%) | |||||
| ≤19 | 5 (0.2) | 26 (2.3) | 6 (1.1) | 50 (31.1) | 32 (12.5) |
| 20–39 | 58 (2.7) | 673 (56.6) | 193 (36.5) | 69 (42.9) | 51 (20.0) |
| 40–64 | 1301 (59.6) | 455 (38.2) | 290 (54.8) | 30 (18.6) | 111 (43.5) |
| ≥65 | 818 (37.5) | 35 (2.9) | 40 (7.6) | 12 (7.5) | 61 (23.9) |
| Race (White), n (%) | 1918 (93.3) | 1009 (91.9) | 463 (92.6) | 139 (82.2) | 208 (86.7) |
| Histopathologic diagnosis, n (%) | |||||
| Glioblastoma | 1918 (87.4) | 297 (24.8) | 2 (0.4) | 59 (28.8) | 152 (56.1) |
| Astrocytoma | 176 (8.0) | 659 (55.0) | 14 (2.6) | 48 (23.4) | 43 (15.9) |
| Oligodendroglioma | 13 (0.6) | 81 (6.8) | 450 (84.8) | 3 (1.5) | 5 (1.8) |
| Other gliomas | 88 (4.0) | 161 (13.4) | 65 (12.2) | 95 (46.3) | 71 (26.2) |
| Grade, n (%) | |||||
| 1 | — | — | — | 21 (16.7) | 16 (8.0) |
| 2 | — | 266 (25.9) | 240 (51.1) | 9 (7.1) | 12 (6.0) |
| 3 | — | 427 (41.5) | 230 (48.9) | 11 (8.7) | 17 (8.5) |
| 4 | 2195 (100.0) | 334 (32.5) | — | 85 (67.5) | 156 (77.6) |
| Molecular alterations, n (%) | |||||
| TERT promoter | 1522 (91.0) | 40 (6.0) | 317 (94.3) | 4 (2.3) | 0 (0) |
| EGFR amplification | 1038 (47.5) | 17 (1.7) | 0 (0) | 6 (3.1) | 0 (0) |
| Whole Chr7 Gain/Chr10 loss | 1231 (57.7) | 8 (0.8) | 1 (0.2) | 2 (1.1) | 0 (0) |
| CDKN2A/B hom. del. | 1234 (56.5) | 99 (10.1) | 8 (1.5) | 17 (8.7) | 81 (29.9) |
| PDGFRA | 248 (11.3) | 77 (6.4) | 20 (3.8) | 33 (16.3) | 40 (14.8) |
| PTEN | 1046 (47.7) | 40 (3.3) | 12 (2.3) | 12 (5.9) | 67 (24.7) |
| ATRX | 58 (2.6) | 733 (61.3) | 34 (6.4) | 65 (32.5) | 55 (20.3) |
| TP53 | 562 (25.6) | 1099 (91.7) | 40 (7.5) | 77 (37.6) | 108 (39.9) |
| Variable . | Glioblastoma . | Astrocytoma (IDH1/2-mut) . | Oligodendro-glioma . | Pediatric-type Glioma . | Other IDH1/2-wild-type gliomas . |
|---|---|---|---|---|---|
| Patients, n | 2195 | 1198 | 531 | 205 | 271 |
| Cohort, n (%) | |||||
| TCGA NCI | 325 (14.8) | 266 (22.2) | 164 (30.9) | 5 (2.4) | 12 (4.4) |
| DFCI/BWH | 791 (36.0) | 358 (29.9) | 176 (33.1) | 96 (46.8) | 144 (53.1) |
| Genie (v10) | 1079 (49.2) | 574 (47.9) | 191 (36.0) | 104 (50.7) | 115 (42.4) |
| Sex (female), n (%) | 886 (40.4) | 483 (40.3) | 250 (47.2) | 95 (46.3) | 115 (42.4) |
| Median age, years (range) | 61 (6-94) | 36 (7-90) | 43 (13-81) | 27 (1-78) | 51 (0-90) |
| Age (years), n (%) | |||||
| ≤19 | 5 (0.2) | 26 (2.3) | 6 (1.1) | 50 (31.1) | 32 (12.5) |
| 20–39 | 58 (2.7) | 673 (56.6) | 193 (36.5) | 69 (42.9) | 51 (20.0) |
| 40–64 | 1301 (59.6) | 455 (38.2) | 290 (54.8) | 30 (18.6) | 111 (43.5) |
| ≥65 | 818 (37.5) | 35 (2.9) | 40 (7.6) | 12 (7.5) | 61 (23.9) |
| Race (White), n (%) | 1918 (93.3) | 1009 (91.9) | 463 (92.6) | 139 (82.2) | 208 (86.7) |
| Histopathologic diagnosis, n (%) | |||||
| Glioblastoma | 1918 (87.4) | 297 (24.8) | 2 (0.4) | 59 (28.8) | 152 (56.1) |
| Astrocytoma | 176 (8.0) | 659 (55.0) | 14 (2.6) | 48 (23.4) | 43 (15.9) |
| Oligodendroglioma | 13 (0.6) | 81 (6.8) | 450 (84.8) | 3 (1.5) | 5 (1.8) |
| Other gliomas | 88 (4.0) | 161 (13.4) | 65 (12.2) | 95 (46.3) | 71 (26.2) |
| Grade, n (%) | |||||
| 1 | — | — | — | 21 (16.7) | 16 (8.0) |
| 2 | — | 266 (25.9) | 240 (51.1) | 9 (7.1) | 12 (6.0) |
| 3 | — | 427 (41.5) | 230 (48.9) | 11 (8.7) | 17 (8.5) |
| 4 | 2195 (100.0) | 334 (32.5) | — | 85 (67.5) | 156 (77.6) |
| Molecular alterations, n (%) | |||||
| TERT promoter | 1522 (91.0) | 40 (6.0) | 317 (94.3) | 4 (2.3) | 0 (0) |
| EGFR amplification | 1038 (47.5) | 17 (1.7) | 0 (0) | 6 (3.1) | 0 (0) |
| Whole Chr7 Gain/Chr10 loss | 1231 (57.7) | 8 (0.8) | 1 (0.2) | 2 (1.1) | 0 (0) |
| CDKN2A/B hom. del. | 1234 (56.5) | 99 (10.1) | 8 (1.5) | 17 (8.7) | 81 (29.9) |
| PDGFRA | 248 (11.3) | 77 (6.4) | 20 (3.8) | 33 (16.3) | 40 (14.8) |
| PTEN | 1046 (47.7) | 40 (3.3) | 12 (2.3) | 12 (5.9) | 67 (24.7) |
| ATRX | 58 (2.6) | 733 (61.3) | 34 (6.4) | 65 (32.5) | 55 (20.3) |
| TP53 | 562 (25.6) | 1099 (91.7) | 40 (7.5) | 77 (37.6) | 108 (39.9) |
Summary table of surveyed gliomas after molecular classification. Calculated percentages for clinical variables or molecular alterations are out of the total number of samples included or assayed per variable. Chr, chromosome; n, number.
| Variable . | Glioblastoma . | Astrocytoma (IDH1/2-mut) . | Oligodendro-glioma . | Pediatric-type Glioma . | Other IDH1/2-wild-type gliomas . |
|---|---|---|---|---|---|
| Patients, n | 2195 | 1198 | 531 | 205 | 271 |
| Cohort, n (%) | |||||
| TCGA NCI | 325 (14.8) | 266 (22.2) | 164 (30.9) | 5 (2.4) | 12 (4.4) |
| DFCI/BWH | 791 (36.0) | 358 (29.9) | 176 (33.1) | 96 (46.8) | 144 (53.1) |
| Genie (v10) | 1079 (49.2) | 574 (47.9) | 191 (36.0) | 104 (50.7) | 115 (42.4) |
| Sex (female), n (%) | 886 (40.4) | 483 (40.3) | 250 (47.2) | 95 (46.3) | 115 (42.4) |
| Median age, years (range) | 61 (6-94) | 36 (7-90) | 43 (13-81) | 27 (1-78) | 51 (0-90) |
| Age (years), n (%) | |||||
| ≤19 | 5 (0.2) | 26 (2.3) | 6 (1.1) | 50 (31.1) | 32 (12.5) |
| 20–39 | 58 (2.7) | 673 (56.6) | 193 (36.5) | 69 (42.9) | 51 (20.0) |
| 40–64 | 1301 (59.6) | 455 (38.2) | 290 (54.8) | 30 (18.6) | 111 (43.5) |
| ≥65 | 818 (37.5) | 35 (2.9) | 40 (7.6) | 12 (7.5) | 61 (23.9) |
| Race (White), n (%) | 1918 (93.3) | 1009 (91.9) | 463 (92.6) | 139 (82.2) | 208 (86.7) |
| Histopathologic diagnosis, n (%) | |||||
| Glioblastoma | 1918 (87.4) | 297 (24.8) | 2 (0.4) | 59 (28.8) | 152 (56.1) |
| Astrocytoma | 176 (8.0) | 659 (55.0) | 14 (2.6) | 48 (23.4) | 43 (15.9) |
| Oligodendroglioma | 13 (0.6) | 81 (6.8) | 450 (84.8) | 3 (1.5) | 5 (1.8) |
| Other gliomas | 88 (4.0) | 161 (13.4) | 65 (12.2) | 95 (46.3) | 71 (26.2) |
| Grade, n (%) | |||||
| 1 | — | — | — | 21 (16.7) | 16 (8.0) |
| 2 | — | 266 (25.9) | 240 (51.1) | 9 (7.1) | 12 (6.0) |
| 3 | — | 427 (41.5) | 230 (48.9) | 11 (8.7) | 17 (8.5) |
| 4 | 2195 (100.0) | 334 (32.5) | — | 85 (67.5) | 156 (77.6) |
| Molecular alterations, n (%) | |||||
| TERT promoter | 1522 (91.0) | 40 (6.0) | 317 (94.3) | 4 (2.3) | 0 (0) |
| EGFR amplification | 1038 (47.5) | 17 (1.7) | 0 (0) | 6 (3.1) | 0 (0) |
| Whole Chr7 Gain/Chr10 loss | 1231 (57.7) | 8 (0.8) | 1 (0.2) | 2 (1.1) | 0 (0) |
| CDKN2A/B hom. del. | 1234 (56.5) | 99 (10.1) | 8 (1.5) | 17 (8.7) | 81 (29.9) |
| PDGFRA | 248 (11.3) | 77 (6.4) | 20 (3.8) | 33 (16.3) | 40 (14.8) |
| PTEN | 1046 (47.7) | 40 (3.3) | 12 (2.3) | 12 (5.9) | 67 (24.7) |
| ATRX | 58 (2.6) | 733 (61.3) | 34 (6.4) | 65 (32.5) | 55 (20.3) |
| TP53 | 562 (25.6) | 1099 (91.7) | 40 (7.5) | 77 (37.6) | 108 (39.9) |
| Variable . | Glioblastoma . | Astrocytoma (IDH1/2-mut) . | Oligodendro-glioma . | Pediatric-type Glioma . | Other IDH1/2-wild-type gliomas . |
|---|---|---|---|---|---|
| Patients, n | 2195 | 1198 | 531 | 205 | 271 |
| Cohort, n (%) | |||||
| TCGA NCI | 325 (14.8) | 266 (22.2) | 164 (30.9) | 5 (2.4) | 12 (4.4) |
| DFCI/BWH | 791 (36.0) | 358 (29.9) | 176 (33.1) | 96 (46.8) | 144 (53.1) |
| Genie (v10) | 1079 (49.2) | 574 (47.9) | 191 (36.0) | 104 (50.7) | 115 (42.4) |
| Sex (female), n (%) | 886 (40.4) | 483 (40.3) | 250 (47.2) | 95 (46.3) | 115 (42.4) |
| Median age, years (range) | 61 (6-94) | 36 (7-90) | 43 (13-81) | 27 (1-78) | 51 (0-90) |
| Age (years), n (%) | |||||
| ≤19 | 5 (0.2) | 26 (2.3) | 6 (1.1) | 50 (31.1) | 32 (12.5) |
| 20–39 | 58 (2.7) | 673 (56.6) | 193 (36.5) | 69 (42.9) | 51 (20.0) |
| 40–64 | 1301 (59.6) | 455 (38.2) | 290 (54.8) | 30 (18.6) | 111 (43.5) |
| ≥65 | 818 (37.5) | 35 (2.9) | 40 (7.6) | 12 (7.5) | 61 (23.9) |
| Race (White), n (%) | 1918 (93.3) | 1009 (91.9) | 463 (92.6) | 139 (82.2) | 208 (86.7) |
| Histopathologic diagnosis, n (%) | |||||
| Glioblastoma | 1918 (87.4) | 297 (24.8) | 2 (0.4) | 59 (28.8) | 152 (56.1) |
| Astrocytoma | 176 (8.0) | 659 (55.0) | 14 (2.6) | 48 (23.4) | 43 (15.9) |
| Oligodendroglioma | 13 (0.6) | 81 (6.8) | 450 (84.8) | 3 (1.5) | 5 (1.8) |
| Other gliomas | 88 (4.0) | 161 (13.4) | 65 (12.2) | 95 (46.3) | 71 (26.2) |
| Grade, n (%) | |||||
| 1 | — | — | — | 21 (16.7) | 16 (8.0) |
| 2 | — | 266 (25.9) | 240 (51.1) | 9 (7.1) | 12 (6.0) |
| 3 | — | 427 (41.5) | 230 (48.9) | 11 (8.7) | 17 (8.5) |
| 4 | 2195 (100.0) | 334 (32.5) | — | 85 (67.5) | 156 (77.6) |
| Molecular alterations, n (%) | |||||
| TERT promoter | 1522 (91.0) | 40 (6.0) | 317 (94.3) | 4 (2.3) | 0 (0) |
| EGFR amplification | 1038 (47.5) | 17 (1.7) | 0 (0) | 6 (3.1) | 0 (0) |
| Whole Chr7 Gain/Chr10 loss | 1231 (57.7) | 8 (0.8) | 1 (0.2) | 2 (1.1) | 0 (0) |
| CDKN2A/B hom. del. | 1234 (56.5) | 99 (10.1) | 8 (1.5) | 17 (8.7) | 81 (29.9) |
| PDGFRA | 248 (11.3) | 77 (6.4) | 20 (3.8) | 33 (16.3) | 40 (14.8) |
| PTEN | 1046 (47.7) | 40 (3.3) | 12 (2.3) | 12 (5.9) | 67 (24.7) |
| ATRX | 58 (2.6) | 733 (61.3) | 34 (6.4) | 65 (32.5) | 55 (20.3) |
| TP53 | 562 (25.6) | 1099 (91.7) | 40 (7.5) | 77 (37.6) | 108 (39.9) |
Summary table of surveyed gliomas after molecular classification. Calculated percentages for clinical variables or molecular alterations are out of the total number of samples included or assayed per variable. Chr, chromosome; n, number.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
